Showing results (31-40 of 101) with videos related to
Sort By:
Pageof 11
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinibTeresa Moran, Ramón Palmero, Mariano Provencio, et al.Lung Cancer (Amsterdam, Netherlands)|December 22, 2019
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinomaJoan Gibert, Sergi Clavé, Max Hardy-Werbin, et al.Journal of Biomedical Informatics|June 23, 2023
Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancerMohan Timilsina, Dirk Fey, Samuele Buosi, et al.International Journal of Cancer|May 10, 2007
Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patientsJoan Maurel, Cristina Nadal, Xabier Garcia-Albeniz, et al.Frontiers in Oncology|November 2, 2023
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12CLucía Notario, Marc Cucurull, Gabriela Cerdà, et al.Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)Balazs Halmos, Eng-Huat Tan, Ross A Soo, et al.BMC Psychology|November 24, 2020
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal studyN Nuria Viñolas, Rosario Garcia-Campelo, Margarita Majem, et al.Oncotarget|January 20, 2016
ROS1 copy number alterations are frequent in non-small cell lung cancerSergi Clavé, Javier Gimeno, Ana M Muñoz-Mármol, et al.Oncotarget|September 10, 2021
Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driverMarta Domènech, Ana M Muñoz Marmol, Jose Luis Mate, et al.Cancers|August 27, 2021
Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung CancerJoaquim Bosch-Barrera, Sara Verdura, José Carlos Ruffinelli, et al.Pageof 11